Routine use of the Ion Torrent AmpliSeq™ Cancer Hotspot Panel for identification of clinically actionable somatic mutations.
about
Technological considerations for genome-guided diagnosis and management of cancerTowards Personalized Medicine in Melanoma: Implementation of a Clinical Next-Generation Sequencing Panel.KRAS and GNAS Co-Mutation in Metastatic Low-Grade Appendiceal Mucinous Neoplasm (LAMN) to the Ovaries: A Practical Role for Next-Generation Sequencing.Distribution of somatic mutations of cancer-related genes according to microsatellite instability status in Korean gastric cancer.Progress and opportunities in molecular pathological epidemiology of colorectal premalignant lesions.Available resources and challenges for the clinical annotation of somatic variationsNext-Generation Sequencing in Oncology: Genetic Diagnosis, Risk Prediction and Cancer Classification.Single-tube, highly parallel mutation enrichment in cancer gene panels by use of temperature-tolerant COLD-PCR.Retrospective review using targeted deep sequencing reveals mutational differences between gastroesophageal junction and gastric carcinomas.Clinical application of a custom AmpliSeq library and ion torrent PGM sequencing to comprehensive mutation screening for deafness genesAssessing the clinical value of targeted massively parallel sequencing in a longitudinal, prospective population-based study of cancer patients.Genotyping-in-Thousands by sequencing (GT-seq): A cost effective SNP genotyping method based on custom amplicon sequencing.Development and validation of the JAX Cancer Treatment Profile™ for detection of clinically actionable mutations in solid tumors.Evaluation and comparison of two commercially available targeted next-generation sequencing platforms to assist oncology decision making.Mutation and Transcriptional Profiling of Formalin-Fixed Paraffin Embedded Specimens as Companion Methods to Immunohistochemistry for Determining Therapeutic Targets in Oropharyngeal Squamous Cell Carcinoma (OPSCC): A Pilot of Proof of Principle.Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology.Effective quality management practices in routine clinical next-generation sequencing.Comparison of next generation sequencing, SNaPshot assay and real-time polymerase chain reaction for lung adenocarcinoma EGFR mutation assessment.BRCA1-2 diagnostic workflow from next-generation sequencing technologies to variant identification and final report.Implementation of a Molecular Tumor Board: The Impact on Treatment Decisions for 35 Patients Evaluated at Dartmouth-Hitchcock Medical Center.Molecular profiling of intrahepatic and extrahepatic cholangiocarcinoma using next generation sequencingCytology smears as excellent starting material for next-generation sequencing-based molecular testing of patients with adenocarcinoma of the lung.Clinical applicability and cost of a 46-gene panel for genomic analysis of solid tumours: Retrospective validation and prospective audit in the UK National Health Service.Validation of targeted next-generation sequencing for RAS mutation detection in FFPE colorectal cancer tissues: comparison with Sanger sequencing and ARMS-Scorpion real-time PCR.Phase II clinical and exploratory biomarker study of dacomitinib in recurrent and/or metastatic esophageal squamous cell carcinoma.Clinical Genotyping of Non-Small Cell Lung Cancers Using Targeted Next-Generation Sequencing: Utility of Identifying Rare and Co-mutations in Oncogenic Driver Genes.Analysis of tumor template from multiple compartments in a blood sample provides complementary access to peripheral tumor biomarkersColorectal Choriocarcinoma in a Patient with Probable Lynch Syndrome.Somatic Mutation Screening Using Archival Formalin-Fixed, Paraffin-Embedded Tissues by Fluidigm Multiplex PCR and Illumina Sequencing.Challenges and opportunities of next-generation sequencing: a cytopathologist's perspective.Reference standards for next-generation sequencing.Quality control material for the detection of somatic mutations in fixed clinical specimens by next-generation sequencing.Sequencing-based diagnostics for pediatric genetic diseases: progress and potentialClinical Outcomes of TP53 Mutations in Cancers.A novel three-round multiplex PCR for SNP genotyping with next generation sequencing.The potential utility of re-mining results of somatic mutation testing: KRAS status in lung adenocarcinomaComparative mutational landscape analysis of patient-derived tumour xenografts.Molecular characterization of CD44+/CD24-/Ck+/CD45- cells in benign and malignant breast lesions.A case of S-100 negative melanoma: A diagnostic pitfall in the workup of a poorly differentiated metastatic tumor of unknown origin.The Pitfalls of Companion Diagnostics: Evaluation of Discordant EGFR Mutation Results from a Clinical Laboratory and a Central Laboratory.
P2860
Q28066706-6C31B7A7-D825-437A-A849-8AFE9B7061CEQ33674041-32F72C36-2576-48B5-84D4-2BDA4DEA9C5CQ33736401-05250112-0A33-488A-A5EE-7038C411ABDDQ33833750-BA902713-472A-478F-9FBB-99DF20B4370DQ34016833-AA54C45A-B562-4CF9-AE7D-DE53189D4241Q34507388-9355D391-A8C8-4FD1-B7F1-9E4783BCD500Q34550417-0D5DBF45-E496-41C0-A421-68B81C0645A9Q34799278-658CF1AC-7841-4E35-95A2-DF701568AA60Q35067345-543B1D4F-5F31-448B-9EE1-62BDA9EE44C2Q35376490-EBCCD2E8-65D7-4243-882F-E16215D333B1Q35475492-6437F545-7B24-4ABF-8E3F-6D16E034A042Q35492595-C3D62228-D50B-40CE-AF53-E12FA7CBCDE5Q35538750-085A7E82-05C0-462D-9AFE-31548097BE57Q35580269-CBF86C16-BF3A-4B62-A08B-6F793F3120D5Q35582737-53C2F17C-4AFB-4CE5-A2B6-E43C26F7A8F3Q35584856-B6A45B87-869F-4CE3-9BD8-CD0D12C98B8CQ35922622-7FE8C52B-2477-457B-814E-F5DF93478029Q36027021-633BA1C4-252B-4600-912B-2C1ED5FE4F3EQ36029740-44949CF1-A833-4FCE-84C7-C5AD00C4AABBQ36064946-E0A9539B-74FD-43A0-B1F2-0AEA575D504AQ36113790-D4C6AD0B-8985-456C-A1F9-83FAC2AA4A69Q36135533-9F924EE4-9B44-42BB-98B9-335A4217DF9BQ36279825-023124F6-A194-41FA-90F2-4261994D6F5FQ36472281-0DB3F68E-D21F-42EA-B502-34ACC71932F2Q36689140-1B6E3635-09AE-4037-A087-9FDA646C663DQ37273873-26676E71-BD62-4C7B-8B4F-536818DC1E38Q37295773-525EB022-BF55-4B8F-89A6-0DB7F444CC58Q37447203-4226A995-2BC2-45E8-AC74-B0F2B0B36541Q38385507-FDD5C7A4-6155-46D9-9811-0A2500F81552Q38591866-D75EE837-74AE-46A7-BF90-1CC28EC72A89Q38669617-19FEC0DB-70CB-40D4-B16D-64A872EA4898Q38834954-96D3EAC0-87EA-4AA1-9C1E-D2DEE748C373Q38844223-833DB604-4AFB-4FE0-B34D-9133CE890860Q38906201-9996EBDD-98AF-47D9-9613-A1F711231DBAQ39822811-448937D4-DB76-4576-AD86-A5E33930715EQ39859156-3E4ECDBC-04E2-411A-AD43-9947A9B2D564Q40366394-E2940DE9-37FC-4BD1-8A74-72C47CF00117Q40367258-FB4ABED1-6465-4BB6-8CEA-92273F6AD661Q41205729-5C17557D-2494-43DF-A573-1963F1C4C889Q47139220-CA6EE099-8BB8-4085-BCE1-BD647B6B57C6
P2860
Routine use of the Ion Torrent AmpliSeq™ Cancer Hotspot Panel for identification of clinically actionable somatic mutations.
description
2014 nî lūn-bûn
@nan
2014 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Routine use of the Ion Torrent ...... actionable somatic mutations.
@ast
Routine use of the Ion Torrent ...... actionable somatic mutations.
@en
type
label
Routine use of the Ion Torrent ...... actionable somatic mutations.
@ast
Routine use of the Ion Torrent ...... actionable somatic mutations.
@en
prefLabel
Routine use of the Ion Torrent ...... actionable somatic mutations.
@ast
Routine use of the Ion Torrent ...... actionable somatic mutations.
@en
P2093
P356
P1476
Routine use of the Ion Torrent ...... actionable somatic mutations.
@en
P2093
Christopher D Tunkey
Christopher I Amos
Francine B de Abreu
Gregory J Tsongalis
Jason D Peterson
Linda D Strausbaugh
Torrey L Gallagher
Wendy A Wells
P304
P356
10.1515/CCLM-2013-0883
P577
2014-05-01T00:00:00Z